BURLINGAME, Calif., Oct. 21 /PRNewswire/ -- Sensorin, which is developing and commercializing a novel self-calibrating pH measurement platform for bioprocess applications, today announced the closing of its second round of equity funding. Use of proceeds from the financing includes product development, beta testing and launch of Sensorin's proprietary pH sensing system. Terms of the financing were not disclosed.
"Sensorin is funded by a distinguished group of individual investors with first-hand biopharmaceutical experience who are aware of the problems associated with current pH probes and who recognize the large commercial opportunity for better in-line pH measurement," said Carolyn Kahn, Ph.D., Sensorin president and CEO. "Sensorin's system represents a compelling solution for bioprocessing, including fixed and disposable fermentation systems and downstream processing."
"Improved pH control has the potential to significantly increase biopharmaceutical yields," commented Frank Jackson, former Vice President of Vacaville Product Operations for Genentech, Inc., and a Sensorin investor and advisor. "Although internally referenced approaches to measuring pH have been explored in academia, Sensorin has developed the only platform capable of in-line pH measurement without calibration, without drift and without fouling during extended periods of cell culture."
Sensorin obtained seed financing and began operations in the third quarter of 2007. The company rapidly demonstrated proof-of-concept for its proprietary technology platform, achieving this goal by the end of 2007. Sensorin is currently developing a beta version of its system for customer testing, with a prospective commercial launch in 2009.
Sensorin intends to address biologics manufacturing with its first-
generation pH measurement system. The technology can be extended to other
industrial pH applications, including waste-water processing and oil, gas
and biofuels production.
Copyright©2008 PR Newswire.
All rights reserved